Gufic BioSciences Ltd.

BSE: GUFICBIO509079ISIN INE742B01025

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹426.60+9.25 (+2.22%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹466.05
52W low: ₹267.50
Off 52W high: -8.46%
1M return: +1.44%
3M return: +8.37%
6M return: +45.60%
1Y return: +30.56%
20D avg volume: 4,618
50 DMA: ₹420.59
200 DMA: ₹354.29

Key ratios Consolidated

Market cap: ₹4,278 Cr
Current price: ₹426.60
52W high / low: ₹466.05 / ₹267.50
Face value: ₹1.00
P/E: 58.24
P/B: 6.43
EPS (TTM): ₹7.32
Book value / share: ₹66.31
ROE: —
ROCE: 14.90%
Operating margin: —
Net margin: —
Debt / equity: 0.58
Net debt: ₹322.98 Cr
Interest cover: 3.36
Dividend yield: 0.02%
Dividend / share (TTM): ₹0.10
Payout: 1.37%
Cash conversion cycle: 163.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	260.82	251.82	231.41	237.06	223.72	205.02	207.79	204.18	202.81	194.99	201.78	214.87
	0.46	1.17	0.79	2.12	0.93	0.40	1.86	0.11	1.25	0.88	0.42	0.33
	261.28	250.65	232.20	239.17	224.65	205.41	209.66	204.29	204.07	195.88	202.20	215.21
	231.24	221.70	214.48	216.57	207.37	194.89	183.40	175.04	175.96	168.76	172.64	184.26
	106.14	124.07	99.27	113.47	88.52	122.91	73.59	74.94	72.77	90.95	72.92	95.29
	14.03	8.94	15.82	25.69	14.27	10.85	15.55	16.57	12.45	14.34	12.00	15.66
	41.80	38.15	40.09	37.45	36.00	35.58	33.96	28.47	29.05	29.60	30.60	26.78
	9.32	9.44	8.36	9.59	9.23	8.40	4.91	5.18	4.62	3.65	3.18	4.46
	7.71	7.65	7.69	7.77	7.72	7.84	4.62	4.30	4.30	4.34	4.14	4.30
	57.41	51.52	57.32	57.32	53.65	53.41	45.75	40.96	43.25	42.55	39.38	39.62
	30.04	28.95	17.72	22.60	17.27	10.53	26.26	29.25	28.11	27.12	29.56	30.95
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	30.04	28.95	17.72	22.60	17.27	10.53	26.26	29.25	28.11	27.12	29.56	30.95
	7.73	7.05	5.30	5.78	4.20	2.81	6.96	7.49	7.25	7.07	7.30	7.74
	22.31	21.90	12.42	16.82	13.07	7.72	19.30	21.77	20.86	20.05	22.26	23.21
	2.22	2.18	1.24	1.68	1.30	0.77	1.93	2.17	2.08	2.00	2.23	2.39
Key metrics
	47.07	46.04	33.77	39.96	34.22	26.77	35.79	38.73	37.03	35.11	36.88	39.71
	18.00%	18.30%	14.60%	16.90%	15.30%	13.10%	17.20%	19.00%	18.30%	18.00%	18.30%	18.50%
	8.60%	8.70%	5.40%	7.10%	5.80%	3.80%	9.30%	10.70%	10.30%	10.30%	11.00%	10.80%
	—	4.70%	—	4.00%	—	2.40%	—	—	—	—	—	—
	16.60%	22.80%	11.40%	16.10%	10.30%	5.10%	3.00%	-5.00%	—	—	—	—
	70.70%	183.70%	-35.60%	-22.70%	-37.30%	-61.50%	-13.30%	-6.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	981.11	944.01	819.81	806.67
	4.54	2.66	3.63	2.18
	983.30	946.66	823.43	808.84
	883.99	860.12	729.29	693.17
	442.95	425.32	344.20	341.32
	64.48	64.71	55.41	58.06
	157.49	151.68	127.05	109.63
	36.71	36.61	23.11	15.36
	30.82	30.83	21.07	17.02
	223.57	219.81	183.36	161.27
	99.31	86.55	94.14	115.67
	0.00	0.00	0.00	0.00
	99.31	86.55	94.14	115.67
	25.86	22.34	24.50	29.54
	73.45	64.21	69.65	86.14
	7.32	6.40	6.95	8.74
Key metrics
	166.84	153.99	138.32	148.05
	17.01%	16.30%	16.90%	18.40%
	7.49%	6.80%	8.50%	10.70%
	—	14.90%	15.00%	—
	16.70%	15.10%	1.60%	—
	18.74%	-7.80%	-19.10%	—
	—	13.79	47.04	—
	—	0.70	1.76	—
	—	0.58	0.52	—
	—	322.98	294.66	—
	—	163.5	166.0	—
Balance sheet
	—	1,342	1,169	—
	—	802.12	624.52	—
	—	62.19	15.72	—
	—	297.40	314.61	—
	—	324.47	216.87	—
	—	101.80	0.00	—
	—	484.85	499.65	—
	—	199.03	158.75	—
	—	517.85	387.56	—
	—	385.17	310.38	—
	—	280.13	179.88	—
	—	105.04	130.50	—
	—	664.99	601.08	—
Cash flow
	—	44.97	122.57	—
	—	-30.96	-70.78	—
	—	32.46	-37.20	—
	—	31.18	75.53	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	260.82	252.05	231.09	230.42	226.91	205.02	207.79	204.18	202.81	194.99	201.78	214.87
	0.46	-1.20	0.79	2.09	0.89	0.38	1.86	0.11	1.25	0.88	0.42	0.33
	261.28	250.86	231.89	232.51	227.81	205.40	209.66	204.29	204.07	195.88	202.20	215.21
	231.11	223.23	210.84	211.98	211.53	194.62	183.38	175.03	175.96	168.76	172.64	184.26
	106.14	124.27	99.07	113.47	88.52	122.91	73.59	74.93	72.77	90.95	72.92	95.29
	14.03	8.95	15.82	25.69	14.27	10.85	15.55	16.57	12.45	14.34	12.00	15.66
	41.80	38.14	40.09	37.45	36.00	35.57	33.96	28.47	29.05	29.60	30.60	26.78
	9.32	9.44	8.36	9.58	9.23	8.40	4.91	5.18	4.62	3.65	3.18	4.46
	7.71	7.65	7.69	7.77	7.72	7.84	4.62	4.30	4.31	4.34	4.14	4.30
	57.28	52.83	53.88	57.27	53.27	53.14	45.73	40.95	43.24	42.55	39.38	39.62
	30.16	27.63	21.05	20.53	16.28	10.78	26.28	29.26	28.11	27.12	29.56	30.95
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	30.16	27.63	21.05	20.53	16.28	10.78	26.28	29.26	28.11	27.12	29.56	30.95
	7.70	7.05	5.49	5.59	4.20	2.81	6.96	7.49	7.25	7.07	7.30	7.74
	22.46	20.57	15.56	14.94	12.07	7.97	19.32	21.78	20.86	20.05	22.26	23.21
	2.24	2.05	1.55	1.49	1.20	0.80	1.93	2.17	2.08	2.00	2.23	2.39
Key metrics
	47.19	44.72	37.10	37.88	33.23	27.02	35.81	38.74	37.04	35.11	36.88	39.71
	18.10%	17.70%	16.10%	16.40%	14.60%	13.20%	17.20%	19.00%	18.30%	18.00%	18.30%	18.50%
	8.60%	8.20%	6.70%	6.50%	5.30%	3.90%	9.30%	10.70%	10.30%	10.30%	11.00%	10.80%
	—	4.50%	—	3.80%	—	2.50%	—	—	—	—	—	—
	14.90%	22.90%	11.20%	12.90%	11.90%	5.10%	3.00%	-5.00%	—	—	—	—
	86.10%	158.10%	-19.50%	-31.40%	-42.10%	-60.20%	-13.20%	-6.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	974.38	940.48	819.81	806.67	690.62	779.16
	2.14	2.58	3.62	2.18	2.57	3.10
	976.54	943.06	823.42	808.84	693.20	782.26
	877.16	857.57	728.99	693.17	586.47	655.42
	442.95	425.32	344.20	341.32	339.36	353.93
	64.49	64.73	55.41	58.06	25.84	77.42
	157.48	151.68	127.05	109.63	86.73	85.61
	36.70	36.61	23.11	15.36	8.22	4.85
	30.82	30.83	21.06	17.02	22.28	17.13
	221.26	217.25	183.07	161.27	137.42	135.87
	99.37	85.48	94.43	115.67	106.72	126.84
	0.00	0.00	0.00	—	—	—
	99.37	85.48	94.43	115.67	106.72	126.84
	25.83	22.34	24.50	29.54	27.02	31.00
	73.53	63.15	69.93	86.14	79.70	95.84
	7.33	6.30	6.97	8.74	8.22	9.89
Key metrics
	166.89	152.92	138.60	148.05	137.22	148.82
	17.13%	16.30%	16.90%	18.40%	19.90%	19.10%
	7.55%	6.70%	8.50%	10.70%	11.50%	12.30%
	—	14.80%	15.00%	—	—	—
	15.46%	14.70%	1.60%	16.80%	-11.40%	—
	20.26%	-9.70%	-18.80%	8.10%	-16.80%	—
	—	12.84	47.26	—	—	—
	—	0.70	1.76	—	—	—
	—	0.58	0.52	—	—	—
	—	324.85	295.47	—	—	—
	—	164.0	166.0	—	—	—
Balance sheet
	—	1,342	1,170	—	—	—
	—	800.26	623.78	—	—	—
	—	60.32	14.91	—	—	—
	—	297.40	314.61	—	—	—
	—	324.47	216.87	—	—	—
	—	101.81	0.00	—	—	—
	—	484.85	499.65	—	—	—
	—	199.08	158.75	—	—	—
	—	517.87	387.53	—	—	—
	—	385.17	310.38	—	—	—
	—	280.13	179.88	—	—	—
	—	105.04	130.50	—	—	—
	—	664.18	601.36	—	—	—
Cash flow
	—	44.02	122.78	—	—	—
	—	-30.96	-71.79	—	—	—
	—	32.36	-37.20	—	—	—
	—	31.18	75.52	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +10.84%
Sales CAGR 5Y: —
Profit CAGR 3Y: -7.47%
Profit CAGR 5Y: —
Sales YoY (TTM): +15.46%
Profit YoY (TTM): +20.26%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +16.70%
Profit YoY (TTM): +18.74%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 72.51%

Quarter	September 2026	June 2026
Promoter %	72.51%	72.51%

Holder	Type	Holding	Previous	Change
Jayesh Pannalal Choksi	Promoter	24.62%	24.62%	0.00%
Zircon Teconica Private Limited	Promoter	20.47%	20.47%	0.00%
Gufic Private Limited	Promoter	10.16%	10.16%	0.00%
Vipula Jayesh Choksi	Promoter	10.01%	10.01%	0.00%
Pranav Jayesh Choksi	Promoter	7.25%	7.25%	0.00%
MOTILAL OSWAL FINANCIAL SERVICES LTD	Public	3.32%	3.32%	0.00%
ICICI PRUDENTIAL MULTI CAP FUND	Public	1.65%	—	—
JAGDISH N MASTER	Public	1.19%	1.41%	-0.22%
GIRISH GULATI (HUF)	Public	1.00%	—	—
Deepika Milan Barot	Promoter Group	0.00%	0.00%	0.00%
Jal Private Limited	Promoter Group	0.00%	0.00%	0.00%
Pooja Pranav Choksi	Promoter Group	0.00%	0.00%	0.00%
Forum Ameet Shah	Promoter Group	0.00%	0.00%	0.00%
Motif Hotels LLP	Promoter Group	0.00%	0.00%	0.00%
Gufic Chem Private Limited	Promoter Group	0.00%	0.00%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,37,952	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,69,451	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,449	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,26,703	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,19,341	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,13,578	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,243	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,03,881	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	1,02,895	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	90,887	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,147	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	61,956	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Biocon Ltd.	58,897	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Abbott India Ltd. S	56,508	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Gland Pharma Limited	51,934	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	49,458	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
Emcure Pharmaceuticals Limited	42,498	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
GlaxoSmithkline Pharmaceuticals Ltd.	42,363	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,012	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	33,915	1,546.30	90.80	18.10%	—	—	+67.49%
Wockhardt Ltd	32,340	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
PIRAMAL PHARMA LIMITED	31,793	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,838	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
RUBICON RESEARCH LIMITED	28,809	1,716.55	98.59	24.30%	—	—	+164.06%
Gufic BioSciences Ltd.	4,365	426.60	58.24	14.90%	+16.70% TTM	+18.74% TTM	+30.56%

Filings & corporate actions

Recent announcements

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith4 Nov 2026 · Company Update / General
Intimation regarding USFDA Pre-Approval Inspection at the Company''s Manufacturing facility situated at Indore, Madhya Pradesh is attached herewith.23 Oct 2026 · Company Update / General
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares17 Oct 2026 · Company Update / Newspaper Publication
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026 is attached herewith6 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith29 Sep 2026 · Company Update / General
Intimation of closure of Trading Window is attached herewith28 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Intimation of Environmental, Social and Governance (''ESG'') Rating is attached herewith28 Sep 2026 · Company Update / General
Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is attached herewith24 Sep 2026 · Company Update / General
Intimation of Credit Rating is attached herewith8 Sep 2026 · Company Update / Credit Rating
Voting Results and Consolidated Scrutinizer Report of 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith7 Sep 2026 · AGM/EGM / AGM
Proceedings of the 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith4 Sep 2026 · AGM/EGM / AGM
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Promotion and Change in Designation of Senior Management Personnel is attached herewith2 Sep 2026 · Company Update / General
Written Transcript of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith21 Aug 2026 · Company Update / Earnings Call Transcript
Newspaper advertisement regarding Special Window for re-lodgement of transfer and dematerialization of physical shares is attached herewith18 Aug 2026 · Company Update / Newspaper Publication
Intimation of Audio Recording of Earnings Conference Call held on August 17, 2026 at 04:30 p.m. is attached herewith17 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026 is attached herewith.15 Aug 2026 · Company Update / Newspaper Publication
Investor Presentation for the Quarter ended June 30, 2026 is attached herewith14 Aug 2026 · Company Update / Investor Presentation
Approval for Incorporation of Subsidiary in the Philippines and Investment by way of Subscription to its Equity Share Capital is attached herewith.14 Aug 2026 · Company Update / Acquisition
Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026 is attached herewith.14 Aug 2026 · Result / Financial Results
Outcome of the Board of Directors Meeting held on Friday, August 14, 2026 is attached herewith.14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Newspaper Advertisement - Notice of 42nd Annual General Meeting of the Company and evoting details is attached herewith.13 Aug 2026 · Company Update / Newspaper Publication
Business Responsibility and Sustainability Report for the Financial Year ended March 31, 2026, is attached herewith12 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the Financial Year 2025-2026 alongwith Notice of 42nd Annual General Meeting is attached herewith.12 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation for book closure and record date for the purpose of 42nd Annual General Meeting and payment of final dividend for the financial year ended March 31, 202612 Aug 2026 · Corp. Action / Record Date
Intimation of 42nd Annual General Meeting, is attached herewith12 Aug 2026 · AGM/EGM / AGM
Intimation of Earnings Conference Call scheduled to be held on August 17, 2026 is attached herewith11 Aug 2026 · Company Update / Analyst / Investor Meet
Gufic Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....10 Aug 2026 · Board Meeting / Board Meeting
Newspaper Advertisement - Notice of the 42nd Annual General Meeting of the Company is attached herewith7 Aug 2026 · Company Update / Newspaper Publication
Intimation for Re-appointment of Mr. Pankaj Jayakumar Gandhi (DIN: 00001858) as the Whole Time Director of the Company is attached herewith.31 Jul 2026 · Company Update / Change in Directorate
Outcome of the Board of Directors Meeting held on Friday, July 31, 2026 is attached herewith31 Jul 2026 · Others / Outcome without intimation
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026 is attached herewith9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Advertisement regarding Notice for transfer of equity shares to Investor Education and Protection Fund (IEPF) Authority is attached herewith8 Jul 2026 · Company Update / Newspaper Publication
Intimation of closure of Trading Window for the quarter ended June 30, 2026 is attached herewith26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Advertisement regarding Special Window for Re-lodgement of Transfer and Dematerialization of physical shares is attached herewith.18 Jun 2026 · Company Update / Newspaper Publication
Written Transcript of Earnings Conference Call held on June 01, 2026 at 04:30 PM is attached herewith.5 Jun 2026 · Company Update / Earnings Call Transcript
Corrigendum and Clarification to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited, is attached herewith2 Jun 2026 · Company Update / General
Corrigendum and Collaboration to Intimation dated May 29, 2026 regarding Subscription to Shares of Saraswat Co-operative Bank Limited is attached herewith2 Jun 2026 · Company Update / General
Intimation for Audio Recording of Earnings Conference Call held on June 01, 2026 at 04:30 p.m. has been attached herewith.1 Jun 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement of Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026 is attached herewith.30 May 2026 · Company Update / Newspaper Publication
Investor Presentation is attached herewith29 May 2026 · Company Update / Investor Presentation

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.1000	28 Aug 2026	28 Aug 2026	—
Final Dividend - Rs. - 0.1000	22 Sep 2025	22 Sep 2025	—
Final Dividend - Rs. - 0.1000	17 Sep 2024	—	—

Board meetings

14 Aug 2026 Board Meeting - Financial Results